MediWound to Present at 11th Annual Wells Fargo Healthcare Conference
August 26 2016 - 8:00AM
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, announces that Company management
will participate at the 11th Annual Wells Fargo Securities
Healthcare Conference taking place from September 7-8, 2016 in
Boston. Gal Cohen, President and Chief Executive Officer, will
deliver MediWound’s presentation on Wednesday, September 7th at
9:20 a.m. Eastern time.
Mr. Cohen’s presentation will be webcast live on
the internet and can be accessed by visiting the Investor Relations
section of the Company’s website at www.mediwound.com. A replay of
the webcast will be archived on the MediWound website for 90 days
following the presentation.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid®, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in
Europe, Israel and Argentina. NexoBrid represents a new
paradigm in burn care management, and clinical trials have
demonstrated, with statistical significance, its ability to
non-surgically and rapidly remove the eschar earlier and without
harming viable tissue.
MediWound's second innovative product,
EscharEx®, is a topical biological drug being developed for
debridement of chronic and other hard-to-heal wounds and is
complementary to the large number of existing wound healing
products, which require a clean wound bed in order to heal the
wound. EscharEx contains the same proteolytic enzyme technology as
NexoBrid, and benefits from the wealth of existing development data
on NexoBrid. In two Phase 2 studies, EscharEx demonstrated
safety and efficacy in the debridement of chronic and other
hard-to-heal wounds, within a few daily applications.
For more information, please visit
www.mediwound.com.
Contacts: |
|
|
|
|
|
Anne Marie Fields |
Sharon Malka |
|
|
|
|
|
Senior Vice
President |
Chief Financial and
Operations Officer |
|
|
|
|
|
LHA |
MediWound |
|
|
|
|
|
212-838-3777 |
ir@mediwound.co.il |
|
|
|
|
|
afields@lhai.com |
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Apr 2024 to May 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From May 2023 to May 2024